Neuronetics

Neuronetics is a publicly traded medical device company headquartered in Malvern, Pennsylvania, focused on developing and commercializing non-invasive neurotechnology for psychiatric and neurological conditions. The company's flagship product, the NeuroStar Advanced Therapy System, is an FDA-cleared transcranial magnetic stimulation (TMS) platform designed to treat major depressive disorder and obsessive-compulsive disorder. NeuroStar works by delivering focused magnetic pulses to targeted regions of the brain, modulating neural activity without the need for medication or surgery. The system is designed for use in clinical outpatient settings, making it accessible through psychiatrists, neurologists, and other mental health practitioners across the United States.

Neuronetics trades on the NASDAQ under the ticker symbol STIM and has established a significant commercial footprint within the mental health treatment landscape. The NeuroStar system has been used to treat more than 100,000 patients across thousands of clinical practices nationwide, representing one of the broadest real-world deployments of TMS technology in the country. The company has built a robust clinical evidence base supporting the safety and efficacy of its platform, which has helped drive adoption among healthcare providers seeking alternatives to pharmacological treatments. These milestones position Neuronetics as one of the more commercially mature companies operating in the non-invasive neuromodulation space.

Neuronetics holds broader significance for the neurotech industry as a demonstration that non-invasive brain stimulation technologies can achieve meaningful clinical scale and commercial viability. By securing FDA clearance, building a nationwide provider network, and accumulating real-world patient outcome data, the company has helped legitimize TMS as a mainstream psychiatric intervention. Its success provides a roadmap for other neurotech companies seeking to translate neurostimulation research into accessible, reimbursable clinical products. As the industry continues to explore brain-computer interfaces and neuromodulation for a wider range of conditions, Neuronetics represents an important precedent for how neurotech can move from innovation to widespread patient impact.